Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2819  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
  » Next article
  » Previous article 
  » Table of Contents
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (226 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

  In this Article
 »  Abstract
 »  Evolution of Lim...
 »  Prevalance
 »  Inheritance Patterns
 »  Phenotypic Features
 »  Diagnostic Aspec...
 »  Evaluation of a ...
 »  Conclusions
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    PDF Downloaded1053    
    Comments [Add]    
    Cited by others 8    

Recommend this journal


Year : 2008  |  Volume : 56  |  Issue : 3  |  Page : 281-288

Limb girdle muscular dystrophies in India

1 Department of Neurology, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India
2 Department of Neurology, Lok Hospitals, Thane, Mumbai, India

Date of Acceptance05-Aug-2008

Correspondence Address:
Satish V Khadilkar
110, New Wing, First Floor, Bombay Hospital, 12, New Marine Lines, Mumbai-400 020
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.43446

Rights and Permissions

 » Abstract 

The recent years have seen remarkable progress in the field of limb girdle muscular dystrophies (LGMDs) with the advances in immunocytochemistry and genetics. Based on this, many subgroups have emerged. Protein products and genes are getting defined and newer mechanisms of disease are being recognized. Limb girdle muscular dystrophies are common in India. The clinical material is plentiful, and from various centers in the country, phenotypes have been studied. With the help of immunocytochemistry, sarcoglycanopathies and dysferlinopathies have been studied. Genetic information on these subgroups is now beginning to emerge. The laboratory facilities are limited and available in select centers in large institutes. Establishment of genetic laboratories and sophisticated muscle pathology techniques will further elucidate the LGMDs in India.

Keywords: Muscular dystrophies, limb girdle OR sarcoglycanopathy OR dysferlinopathy, India

How to cite this article:
Khadilkar SV, Singh RK. Limb girdle muscular dystrophies in India. Neurol India 2008;56:281-8

How to cite this URL:
Khadilkar SV, Singh RK. Limb girdle muscular dystrophies in India. Neurol India [serial online] 2008 [cited 2023 Mar 24];56:281-8. Available from: https://www.neurologyindia.com/text.asp?2008/56/3/281/43446

 » Evolution of Limb Girdle Muscular Dystrophies in India Top

The historical descriptions of limb girdle muscular dystrophy (LGMD) date back to the late eighteenth century when Erb and Leyden-Mobius described patients having weakness which primarily involved the shoulder and the hip girdles respectively, spared the facial muscles, and were more benign than psuedohypertrophic form described by Duchenne . In 1951, Levison, [1] in his classification, documented for the first time, the autosomal recessive nature of LGMD. In 1953, Stevenson [2] introduced the term 'autosomal limb girdle muscular dystrophy', for his non-Duchenne types with autosomal recessive inheritance. In 1954, Walton and Nattrass [3] defined LGMD as a distinct nosological entity. In the ensuing years, development of diagnostic methods made it evident that LGMD, as originally defined by Walton and Nattrass, was composed of a wide variety of neuromuscular disorders, for example, Kugelberg Wealander disease, polymyositis, endocrine myopathies, and some congenital and metabolic myopathies. This was when the diagnosis went in disrepute. Gardner Medwin omitted the term from the classification. Walton, in 1981 [4] altered his approach to this nosological problem. He retained the term limb girdle muscular dystrophy to designate a major category of dystrophy comprising four subtypes : 1) Autosomal recessive or sporadic (Erb, Leyden-Mobius) 2) Myopathy limited to quadriceps 3) Autosomal recessive muscular dystrophy in childhood and 4) Late onset Autosomal dominant type. The lack of uniformity of available classifications raised the issue as to what constituted the specific entity of LGMD.

In the recent times, the advancement of molecular biology and immunological methods has seen the formation of subgroups based on molecular genetics and deficient components. Many types of autosomal recessive and dominant LGMDs based on genetic information or on protein deficiencies have been now described and newer types are being identified at a rapid pace.

Since decades, across neuromuscular centers in India, dystrophies have been documented which were clearly distinct from the then well-described dystrophinopathies, myotonic disorders, fascio-scapulo humeral dystrophies and the likes. Initial observations on LGMD in India were made in 1975, when Srinivas, in a survey of 211 patients of myopathies seen over 25 years, diagnosed almost half the patients to have muscular dystrophy. Amongst them, 82 were Duchenne Muscular Dystrophy (DMD), 35 LGMD, five fascio-scapulo humeral dystrophies and 14 ocular-oculopharyngeal myopathies. [5] In a hospital-based study of 126 cases of muscular dystrophy by Mondkar and Bhabha, [6] 12 were designated as "girdle dystrophy" (three females) as they did not fit in Duchene or Becker muscular dystrophies. Four cases (three males) with affected sisters were labeled "Autosomal recessive dystrophy of childhood". In1998, Das published a large series of 1950 biopsy-proven myopathies, of which 535 were dystrophies. Among them, 29.2% were labeled as LGMDs, 5.6% severe dystrophies were seen in young girls, resembling DMD and 2.2% had autosomal recessive dystrophies in young boys. [7] In the more recent times, immunocytochemical stains have been used to study Indian patients with LGMDs and information based on immunostaining has emerged. Initial case reports of "Adhalinopathy" (alpha-sarcoglycanopathy) appeared in 2001. [8],[9],[10] This was followed up by case reports of beta and gamma-sarcoglycanoathy from pediatric centers in New Delhi. [11],[12] In 2002, the first series analyzing 25 cases of sarcoglycanopathy came from a neuromuscular center in Mumbai, where phenotypic features were studied in detail and some unique features were pointed out. [13],[14],[15] Soon, as more and more centers across the country got involved with immunostaining of myopathies, further reports, one from New Delhi in 2004, a study of 13 pediatric cases [16] and the other from Hyderabad in 2007, detailing 26 adult cases of sarcoglycanopathies became available. [17] Indeed, sarcoglycanopathy is the best characterized LGMD in India. The second type of LGMD to be immunocharacterized in India is dysferlinopathy. The initial series of 14 Indian patients with dysferlinopathy from Mumbai was published in 2004. [18] The second study comprising nine cases was recently reported from northern India by Pradhan in 2008. [19] A third series comprising 28 patients from south India has been made available in 2008. [20] Genetic evaluation of LGMDs is only recently being reported and is essentially related to small samples. Due to the complexity of LGMD genetics, it seems to have lagged behind other common neuromuscular disorders like spinomuscular atrophy [21] and dystrophinopathies.

 » Prevalance Top

Due to the heterogeneity of LGMD and the lack of diagnostic specificity, estimates of prevalence for all forms of LGMD have ranged from 1 per 14500 to 1 per 123000 populations. In the Indian setting, it is difficult to know the exact prevalence. In a hospital-based survey in a neuromuscular clinic in Mumbai, approximately one-fourth of all patients had LGMD. In adulthood, LGMD formed the most common diagnosis in the group of muscular dystrophies. The series by Das and Mondkar also quote similar figures. This is interesting as LGMDs were far commoner than myotonic disorders, which form the most common adulthood myopathies in some populations. However, given the diversity of ethnicity and genetic background of Indian populations, further systematic and multi-center information is needed to make a useful assessment of the prevalence of LGMD.

 » Inheritance Patterns Top

India is a vastly populous country with diverse cultural conglomerates. In general, autosomal recessive forms of LGMD outnumber the dominant forms. In some communities in India, consanguinity is customary and may be leading to increase in autosomal recessive transmission of LGMDs. Another noteworthy point is the apparent lack of family history in patients with LGMDs. In hospital-based data of 15 years from Mumbai, only 30% patients with LGMD had family history of the disease. This is perplexing and the reason why we do not actually pick up the autosomal recessive states in a proportion of our patients is possibly due to the inadequate ancestoral information given by them and lack of available family members for examination. In the neuromuscular center at Mumbai, social worker inputs in getting together the family members has increased the yield of the number of familial cases to some extent. Autosomal dominant LGMDs are seen less often. In one study at Mumbai, 37 recessive and five dominant cases were encountered. [14] At times, due to deeply inbred population, as seen in certain communities in our country, pseudo-dominance may be encountered.

 » Phenotypic Features Top

LGMD has been prospectively analyzed in many centers across the country. As mentioned earlier, it is the most common adult onset muscular dystrophy encountered in our country. Thanks to a large number of cases, robust clinical data has been generated. Particular attention has been devoted to the phenotype. As a result, interesting signs were described by authors. [15],[19] Among LGMDs in India, sarcoglycanopathy has been most extensively studied followed by dysferlinopathy. With time, as further facilities are obtained, information on other subtypes is expected to emerge.


As of today, there have been three large series of sarcoglycanopathy, one each from the western, northern and southern part of our country, thus incorporating patients of diverse origins across all age groups. [13],[16],[17] The phenotype has been well elucidated and consistent through all the series. [Table 1] gives a comparative account of the three series.

The most commonly noted phenotype of sarcoglycanopathies has been of hip-girdle weakness predominantly involving thigh adductors and knee flexors. The abductors are not much affected till late in the illness. Hence patients do not waddle. In the thigh, hamstrings and quadriceps are both affected and the relative severity is variable. The upper limbs are less involved and the biceps tend to be weaker than the deltoid muscle. Thus in certain ways, the clinical involvement of sarcoglycanopathies is different from Becker muscular dystrophy wherein the hip abductors and quadriceps are affected more severely.
"Hip-abduction sign" (splaying of thighs while getting up from squatting position) is the result of differential weakness between thigh adductors and abductors, the latter being strong. [15] The consistency with which this sign is observed is noteworthy. Some patients learn tricks to prevent splaying of thighs by bringing the knees together and supporting the outer aspects of the thighs with hands. The sign comes to the clinical notice early in the disease course due to the prevalent floor toilet system in India. Some patients report intriguing initial complaints like inability to move the leg from the accelerator to the brake, thighs splaying while performing sit-ups and also while getting up from the ground. Although the sign is a useful clue while evaluating a dystrophy case, it is not specific for a subtype of LGMDs and is seen beyond sarcoglycanopathies. It actually denotes stronger abductors and weaker adductors and has a differential diagnosis.

Distal weakness was consistently noted in adult onset sarcoglycanopathies from Mumbai. It was moderate in severity. This has not been commonly mentioned in world literature. Sarkar et al. , [16] did not notice any distal weakness in their mostly pediatric case series. Phenotypic variability is quite common in LGMDs. Severe weakness in childhood, which is SCARMD, is usually the result of alpha and gamma-sarcoglycan [SG] mutations worldwide. [22],[23] In the Indian series it was secondary to almost all SGs, [15],[16],[21] based on immunodiagnosis. One of our families, a brother and sister sib ship with SCARMD phenotype, [24] did not show deletions in any of the known sarcoglycan genes. This is in accordance with the fact that SCARMD phenotype can result from other mutations. [25] When female members are not affected, the differentiation from DMD becomes difficult. Patients with DMD are more likely to have significant heart involvement and mental sub-normality than LGMD. The severity of clinical presentation varies greatly in the group of sarcoglycanopathies. At one end there is the severe DMD phenotype with early disability and reduced life expectancy. On the other hand, milder forms allowing ambulation till the third and fourth decades are seen. The genotype-phenotype correlation is complex and all the genotypes can result in variable phenotypes. However, alpha and gamma sarcoglycanopathies tend to have severe presentation. As seen from [Table 1], milder presentations of sarcoglycanopathies are not uncommon in India.


The author and colleagues have identified 14 patients having dysferlin deficiency. [18] Patients presented towards the latter half of the second decade. Nine patients had distal presentation and the remaining five had proximal weakness. In the Indian context, where patients squat to defecate, weakness of hip girdle muscles comes to light early. So it is very likely that those who presented with weakness did not have proximal weakness at that stage of the illness and hence truly represent distal onset. However, when they were examined for the first time two or three years into the illness, the weakness tended to be proximal as well. Asymmetry of muscle weakness was noted in six patients. Three patients experienced initial calf pains with transient hypertrophy, followed by atrophy. Gastrocnemius and tibialis were almost similarly affected. The brunt of the proximal weakness was on iliopsoas, hip adductors, hamstrings and quadriceps. Upper limbs were mildly affected. Overall, the phenotype was mild and ambulation was maintained late in the disease course. In a recent paper by Nalini and Gayathri, of 28 patients, [20] dysferlinopathy comprised 23% of total LGMD cases. This series highlighted two patterns of clinical presentations. Patients of Miyoshi myopathy phenotype had initial gastrocnemius weakness and those with LGMD2B had proximal hip girdle weakness. Few patients had initial simultaneous involvement of both proximal and distal muscles. As the disease progressed, other groups of muscles got affected. Upper limb involvement was noted in the form of deltoid and biceps atrophy. Initial muscle pain was noted in 46% of cases. Most patients had disease onset between 15-30 years of age (mean age 21years). Mean age at the time of presentation was 27.9 years. Ambulation was maintained till late in the disease.

The series by Pradhan et al. , [24] focuses on the clinical features of patients showing dysferlin deficiency on immunostaining. A specific appearance of the shoulder girdle, simulating calf head on trophy, has been noted in patients with Miyoshi myopathy. [Table 2] compares the three available series of dysferlinopathies from India. As can be seen from these three papers, disability tends to be mild in dysferlinopathy patients and ambulation is maintained for a long time in the illness.

Selectivity of involvement muscle groups is a hallmark of dystrophy. Such selective wasting within the same muscle results in a unique appearances of muscle mass. 'Lumps and bumps' of quadriceps in sarcoglycanopathy [13] [Figure 1], 'Biceps lump [18] [Figure 2], 'diamond sign' (prominence of anterolateral aspect of thigh on partial contraction of quadriceps) in dysferlinopathy, [19] 'calf-head sign' in Miyoshi myopathy [26] and valley sign [27] are some examples. Biceps lump is believed to be the result of partial involvement of biceps muscle. It was initially described by Fardeu and colleagues from Paris and is believed to be seen most often in dysferlinopathy. Valley sign, a depression created by selective wasting of posterior axillary fold muscles bordered by relatively preserved deltoid superiorly and infraspinatus inferiorly, described by Pradhan mainly in DMD, [27] has been seen in some patients with LGMDs. [17]

Symptomatic cardiac involvement like cardiomyopathy is relatively uncommon in autosomal recessive LGMDs but patients tend to have subclinical abnormality of ECG and echocardiograms, especially T-wave inversions, left ventricular hypertrophy and right bundle branch block. [17],[28] In contrast, a larger proportion of autosomal dominant LGMD patients have significant cardiac disease, like cardiomyopathy or conduction blocks. [18]

Central nervous system abnormalities, especially mental retardation have been recently described in LGMD2K and 2I, which occur due to mutations in the POMT1 and fukitin proteins respectively. [29],[30],[31] This protein is also expressed in the brain and hence mental sub-normality results. In our series, we encountered an AR-SCARMD phenotype in a brother and sister with mental retardation and generalized chorea. Proband had normal dystrophin and sarcoglycan staining. [24] All known sarcoglycan genes were normal. Immunoblot for alpha-dystroglycan is not yet available with us. One unpublished family of two siblings with mental sub-normality and proximal and distal weakness having POMT1 gene abnormality is being followed up at Mumbai.

Description of calpainopathy is currently lacking in the Indian literature, mainly due to the unavailability of immunoblotting techniques. Phenotype suggestive of calpainopathy has been seen. In our series of LGMD at Mumbai, we have come across five sporadic patients with the typical phenotype of severe scapular winging without facial weakness [Figure 3a, b]. They had normal sarcoglycan and dysferlin staining, but had not as yet undergone calpain immunoblotting.

Autosomal dominant LGMDs are less common. We could identify five cases. The most distinct feature was the severe cardiac ailment noted in four of them. In fact one of our patients was referred from the cardiology department where he was admitted with cardiomyopathy. In a family of three brothers and three affected generations, the index case had cardiac pacemaker implanted for heart block, the other two brothers had muscular dystrophy and cardiac abnormalities. This family very likely represents autosomal dominant LGMD of the laminopathy type.

 » Diagnostic Aspects of LGMD in India Top

In the diagnostic workup of suspected LGMD in India, after biochemistry and electrophysiology tests, muscle biopsy is often performed. It is done to establish the dystrophic nature of the process and to rule out alternative causes of muscle weakness. The chosen muscle is the one with moderate weakness. Histology with the conventional H&E staining helps to the establish the nature of the dystrophic process by demonstrating the variation of fiber size, internalization of nuclei, splitting of fibers, myonecrosis, myophagia and changes in connective tissue. [Figure 6] shows early dystrophic changes in an 11-year-old girl with sarcoglycanopathy. Presence of inflammatory cells has been noted in various types of LGMDs, especially in dysferlinopathy. The inflammatory cells often lead to an erroneous diagnosis of inflammatory myopathy and hence evaluation of all changes in the biopsy is important. Alone, histology has a limited role and needs be followed up with immunocytochemistry.

Immunocytochemical analysis of the frozen muscle tissue using monoclonal antibodies for dystrophin, sarcoglycans, dysferlin and merosin is now regularly performed in dedicated neuromuscular centers across India. The results of sarcoglycan staining have been variable among different centers in India. While the study from Mumbai found multiple SG deficiency as the most common pattern, others had either gamma [16] or alpha SG deficiency. [17] Reasons for this discrepancy could be different age groups of patients, early or late stages of the disease or speculatively, even ethnicity of the studied population. As yet, it is not possible to know which type of sarcoglycan deficiency is the most prevalent in India. [Figure 7] shows various patterns of abnormalities of sarcoglycan immunostaining. It needs to be pointed out here that immunocytochemistry has its own inherent limitations. The sarcoglycan hypothesis forwarded by Mizuno [32] states that if one of the SG subunits is absent, the whole complex gets deficient on the muscle membrane. The implication is that on staining patterns alone without genetic studies, it is difficult to know the primary abnormality. Also, no immunostaining pattern is considered specific for a particular sarcoglycan deficiency. To make matters worse, there is complex interaction of sarcoglycans with dystrophin and dysferlin and other stains, which can be secondarily deficient. Immunoblotting techniques can further improve the diagnostic accuracy by quantitating the protein. The differences in the accuracy of quantitative and qualitative assessment are well known. Moreover some subgroups like calpainopathy cannot be confirmed without western blotting. Hence for a confident diagnosis of an LGMD subtype it is preferable to study all available immunostains, quantitate them by western blotting and also study the genes.

Magnetic resonance imaging (MRI) is noninvasive and easily available in our country. It clearly demonstrates the selectivity of muscle weakness [Figure 4 a, b]. At times, in a difficult case, choice of muscle for biopsy can be guided by the MRI findings. Biochemical characterization of LGMD muscle tissue was done by Sharma and Sarkar [33] by MRI-spectroscopy. They found reduced choline, glucose and glutamine in the affected muscles.

In dysferlinopathy, peripheral blood can be studied for the dysferlin western blotting to help the diagnosis [Figure 5]. However, this does not completely obviate the need for muscle biopsy and genetic tests.

Genetics of Sarcoglycanopathies in India

As yet, there is very little information available on the genetics of sarglycanopathies in India. In a small study from Mumbai, 18 patients were identified to have sarcoglycanopathies on the basis of abnormalities detected by the DHPLc-based gene analysis. Gamma sarcoglycan abnormalities were most frequent, followed by alpha, delta, and a single patient with beta sarcoglyanopathy was documented. Amongst the gamma sarcoglycanopathies, the prevalence of 525 del T was noteworthy. This abnormality is seen in select Mediterranean populations and its occurrence in western India is curious. This may be related to the patterns of human migration or may simply reflect this to be a hotspot region.

 » Evaluation of a Patient with LGMD Top

Approach to a patient with limb girdle weakness entails detailed history and clinical examination. It pays to take in-depth family history and examine the family members, to narrow down the differential diagnosis. Particular attention is paid to the phenotype, which gives some clue to the type of LGMD. Electrophysiology and laboratory tests including CPK, toxic and metabolic screen are done as part of diagnostic workup. To distinguish LGMD from dystrophinopathy can be a problem, especially in a young boy with severe weakness (SCARMD phenotype). Dystrophin immunostaining and Polymerase chain reaction (PCR)-based dystrophin gene analysis are available in many centers across India, to help this differential diagnosis.

The broad classification of a patient in the LGMD group is essentially clinical and is based on the common features of transmission and phenotypic expression. However, focusing on a subtype of LGMD is not clinically feasible given the phenotype-genotype heterogeneity. The subgrouping is relevant to the genetic counseling issues and to an extent, may be a predictor of the course of illness and the cardiac involvement as well. Establishing the specific subtype of LGMD in a given patient needs detailed immunocytochemical analysis for various muscle proteins. Demonstration of partial or complete deficiencies of a particular protein in immunostaining should ideally be followed up with mutation studies of the corresponding gene. It is important to realize that immunocytochemistry has limitations and it is difficult to base the gene search based only on immunocytochemical findings.

 » Conclusions Top

Limb girdle muscular dystrophies form an important and common group of myopathies in India. Only two subgroups, sarcoglycanopathies and dysferlinopathies have been characterized up to a point. The diagnostic aspects are still evolving and genetic information is lacking. With wider availability of tests, more information about this group of myopathies will come to the fore.

 » References Top

1.Levision H. Dystrophia musculorum progressiva: Clinical and Diagnostic Criteria. Acta Psy Scand (Suppl) 1951;76:7-175.   Back to cited text no. 1    
2.Stevenson. Muscular dystrophy in Northern Ireland. Ann Hum Genet 1955;19:159-64.   Back to cited text no. 2    
3.Walton JN, Nattrass FJ. On the classification, natural history and treatment of the myopathies. Brain 1954;77:169-231.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Walton JN, Gardner-Medwin D. Progressive muscular dystrophy and the myotonic disorders. In: Walton J, editor. Disorders of voluntary muscle. 4th ed. Edinburgh: Churchill Livingstone; 1981. p. 481-524.  Back to cited text no. 4    
5.Srinivas K. The myopathies (1950-1975). Proc Inst Neurol 1975;5:102-12.  Back to cited text no. 5    
6.Mondkar VP, Bhabha SK. Analysis of 126 cases of muscular dystrophy. J Postgrad Med 1984;30:224-8.  Back to cited text no. 6  [PUBMED]  Medknow Journal
7.Das S. Diagnosis of muscular dystrophies-the changing concepts. Neurol India 1998;46:165-76.  Back to cited text no. 7    
8.Handa V, Mital A. Deficiency of 50kda dystrophin associated glycoprotein (adhalin) in an Indian autosomal recessive LGMD patient: Immunochemical analysis and clinical aspects. Neurol India 2001;49:19-24.  Back to cited text no. 8  [PUBMED]  Medknow Journal
9.Dua T, Kalra V, Sharma MC, Kabra M. Adhalin deficiency: An unusual cause of muscular dystrophy. Indian J Pediatr 2001;68:1083-5.  Back to cited text no. 9    
10.Joshi S. DMD in a female child. Indian Pediatr 2002;39:98.  Back to cited text no. 10  [PUBMED]  [FULLTEXT]
11.Kapoor S, Tatke M. Beta sarcoglycanopathy. Indian J Pediatr 2005 72;1:71-4.  Back to cited text no. 11    
12.Gulati S, Leekha S. Gamma sarcoglycanopathy. Indian J Pediatr 2003 40;1077-81.  Back to cited text no. 12    
13.Khadilkar SV, Singh RK, Katrak SM. Sarcoglycanopathies: A report of 25 cases. Neurol India 2002;50:27-32.  Back to cited text no. 13  [PUBMED]  Medknow Journal
14.Khadilkar SV, Singh RK. Current concepts in Limb girdle muscular dystrophy. Does hip adductor weakness mark the Indian phenotype? In: Mehndiratta MM, Choudhary D, editors. New Delhi: Reviews in Neurology; 2000. p. 34-43.  Back to cited text no. 14    
15.Khadilkar SV, Singh RK. Hip abduction sign: A new clinical sign in sarcoglycanopathy. J Clin Neuromusc Dis Sep 2001;3:13-5.  Back to cited text no. 15    
16.Sharma MC, Mannan R, Singh NG, Gulati G, Kalra V, Sarkar C. Sarcoglycanopathy; An enigmatic form of muscular dystrophy: a report of 7 cases. Neurol India 2004;52:446-9.  Back to cited text no. 16  [PUBMED]  Medknow Journal
17.Meena AK, Sreenivas D, Sundaran C, Rajshekar R, Sita JS. Sarcoglycanopathy: A clinico-pathological study. Neurol India 2007;55:117-21.  Back to cited text no. 17  [PUBMED]  Medknow Journal
18.Khadilkar SV, Singh RK, Kulkarni KS, Chitale AR. A study of clinical and laboratory features of 14 Indian patients with dysferlinopathy. J Clin Neuromusc Dis 2004;6:1-8.  Back to cited text no. 18    
19.Pradhan S. Diamond on quadriceps: A frequent sign in dysferlinopathy. Neurology 2008;70:322.  Back to cited text no. 19  [PUBMED]  [FULLTEXT]
20.Nalini A, Gayathri N. Dysferlinopathy: A clinical and histopathological study of 28 patients from India. Neurol India 2008;56:384-390.  Back to cited text no. 20    
21.Dastur RS, Khadilkar SV, Udani VP, Gaitonde PS, Nadkarni JJ. Correlation between deletion patterns of SMN and NAIP genes and the clinical features of SMA in Indian patients. Neurol India 2006;54:255-9.  Back to cited text no. 21  [PUBMED]  Medknow Journal
22.Bushby KM. Making sense of limb girdle muscular dystrophies. Brain 1999;122:1403-20.   Back to cited text no. 22  [PUBMED]  [FULLTEXT]
23.Duggan DJ, Gorospe JR, Fannin M. Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med 1997;336:618-24.  Back to cited text no. 23    
24.Khadilkar SV, Menezes K, Singh RK, Hegde MR. SCARMD, mental retardation and chorea. Neurol India 2006;54:293-5.  Back to cited text no. 24  [PUBMED]  Medknow Journal
25.Frosk P, Wesler T, Nyler E, Sudha T, Greenberg CR, Moggan K, et al. LGMD2H associated with mutation in TRIM32: A putative E3-ubiquitin-ligase gene. Am J Hum Genet 2002;70:663-72.  Back to cited text no. 25    
26.Pradhan S. Calf-Head sign in Miyoshi myopathy. Arch Neurol 2006;63:1414-7.  Back to cited text no. 26  [PUBMED]  [FULLTEXT]
27.Pradhan S. Valley sign in BMD and DMD/BMD outliers. Neurol India 2004;52:203-5.  Back to cited text no. 27  [PUBMED]  Medknow Journal
28.Rajashekar Reddy G, Meena AK, Srinivas D, Vanaja V, Srinivas B, Goutham PS, et al. A case controlled study of cardiac involvement in LGMD. Indian Heart J 2004;56:363.  Back to cited text no. 28    
29.Muntoni F. Journey into muscular dystrophy caused by abnormal glycosylation. Acta Myol 2004;23:79-84.  Back to cited text no. 29  [PUBMED]  
30.Balchi B, Uyanik G, Dincer P, Gros C, Willer T, Talim B, et al. An autosomal recessive LGMD 2 with mild mental retardation is allelic to Walker-Warburg synd (WWS) caused by a mutation in POMT1 gene. Neuromusc Disord 2005;15:271-5.  Back to cited text no. 30    
31.Brockington M, Yuva Y, Pradini P. Mutations in Fukitin related protein gene (FKRP) identify LGMD2I as a milder allelic variant of congenital muscular dystrophy MDCIC. Hum Mol Genet 2000;10:2851-9.  Back to cited text no. 31    
32.Mizuno Y, Noguchi S, Yoshida M. Selective defect of sarcoglycan complex in SCARMD muscle. Biochem Biophys Res Commun 1994;203:979-83.  Back to cited text no. 32    
33.Sharma U, Atri S, Sharma M C, Sarkar C, jagannathan NR. Biochemical characterization of muscle tissue of LGMD: An 1H and 13C NMR study. NMR Biomed 2003;16:231-3.   Back to cited text no. 33    


  [Figure 1], [Figure 2], [Figure 3a, b], [Figure 4 a, b], [Figure 5], [Figure 6], [Figure 7]

  [Table 1], [Table 2]

This article has been cited by
1 Mutational Spectrum of CAPN3 with Genotype-Phenotype Correlations in Limb Girdle Muscular Dystrophy Type 2A/R1 (LGMD2A/LGMDR1) Patients in India
Pankaj Pathak, Mehar Chand Sharma, Pankaj Jha, Chitra Sarkar, Mohammed Faruq, Prerana Jha, Vaishali Suri, Rohit Bhatia, Sumit Singh, Sheffali Gulati, Mohammad Husain
Journal of Neuromuscular Diseases. 2021; 8(1): 125
[Pubmed] | [DOI]
2 Challenges and Advances in Molecular Diagnosis of Myopathies and Dystrophies in Perspective of Their Use in Developing Countries: Past, Present, and Future
Shivangi Attri, SureshK Gahlawat
Neurology India. 2021; 69(4): 797
[Pubmed] | [DOI]
3 Myositis mimics
Sujata Ganguly, Rudrarpan Chatterjee, Abhishek Zanwar, Latika Gupta
Indian Journal of Rheumatology. 2021; 16(4): 427
[Pubmed] | [DOI]
Beena Vasanthy, Vijayan Chandrathil Parameswaran Nair
Journal of Evidence Based Medicine and Healthcare. 2018; 5(41): 2907
[Pubmed] | [DOI]
5 A first-line diagnostic assay for limb-girdle muscular dystrophy and other myopathies
Dorota Monies,Hindi N. Alhindi,Mohamed A. Almuhaizea,Mohamed Abouelhoda,Anas M. Alazami,Ewa Goljan,Banan Alyounes,Dyala Jaroudi,Abdulelah AlIssa,Khalid Alabdulrahman,Shazia Subhani,Mohamed El-Kalioby,Tariq Faquih,Salma M. Wakil,Nada A. Altassan,Brian F. Meyer,Saeed Bohlega
Human Genomics. 2016; 10(1)
[Pubmed] | [DOI]
6 Oxidative Stress, NF-?B and the Ubiquitin Proteasomal Pathway in the Pathology of Calpainopathy
Dhanarajan Rajakumar,Mathew Alexander,Anna Oommen
Neurochemical Research. 2013; 38(10): 2009
[Pubmed] | [DOI]
7 Phenotypic and immunohistochemical characterization of sarcoglycanopathies
Ferreira, A.F.B. and Carvalho, M.S. and Resende, M.B.D. and Wakamatsu, A. and Reed, U.C. and Marie, S.K.N.
Clinics. 2011; 66(10): 1713-1719
8 Clinical and magnetic resonance imaging features of ′diamond on quadriceps′ sign in dysferlinopathy
Pradhan, S.
Neurology India. 2009; 57(2): 172-175


Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow